Walleye Capital’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VKTX
VCM
VPM
Walleye Capital's VKTX Position: Q1 2026 in Review
Walleye Capital reduced its Viking Therapeutics (VKTX) stake by 95% in Q1 2026, selling an estimated $2.63M and leaving 4,573 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #3499.
Walleye Capital first reported a position in VKTX in Q3 2018 and has held it in 17 quarters since. The position peaked at $3.04M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Walleye Capital held 4,573 shares of Viking Therapeutics worth $149K as of Q1 2026.
- Walleye Capital sold 81,798 Viking Therapeutics shares in Q1 2026, an estimated $2.63M.
- Viking Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3499 holding.
- Walleye Capital first reported a position in Viking Therapeutics in Q3 2018 and has held it in 17 quarters since.
- Walleye Capital's Viking Therapeutics position peaked at $3.04M in Q4 2025.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.